144 related articles for article (PubMed ID: 32886311)
1. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.
Shpoliansky M; Roggenbuck D; Pinsker M; Salamon N; Weiss B; Shouval DS; Werner L
Dig Dis Sci; 2021 Aug; 66(8):2619-2626. PubMed ID: 32886311
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
[TBL] [Abstract][Full Text] [Related]
4. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
[TBL] [Abstract][Full Text] [Related]
7. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.
Duman AE; Hülagü S; Çelebi A; Korkmaz U; Musul MM; Şentürk Ö; Şirin G; Yılmaz H; Koç DÖ; Dindar G; Öztürkler M; Bozkurt N; Kır HM
Turk J Gastroenterol; 2019 Jan; 30(1):21-27. PubMed ID: 30465525
[TBL] [Abstract][Full Text] [Related]
11. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
[TBL] [Abstract][Full Text] [Related]
12. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
Roggenbuck D; Vermeire S; Hoffman I; Reinhold D; Schierack P; Goihl A; von Arnim U; De Hertogh G; Polymeros D; Bogdanos DP; Bossuyt X
Clin Chem Lab Med; 2015 Aug; 53(9):1349-57. PubMed ID: 25411995
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
[TBL] [Abstract][Full Text] [Related]
14. Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.
Kohoutova D; Drahosova M; Moravkova P; Rejchrt S; Bures J
BMC Gastroenterol; 2014 Dec; 14():190. PubMed ID: 25551469
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of anti-glycan antibodies in pediatric Crohn's disease in comparison with an adult cohort.
Rieder F; Hahn P; Finsterhoelzl L; Schleder S; Wolf A; Dirmeier A; Lopez R; Shen B; Rogler G; Klebl F; Lang T
Inflamm Bowel Dis; 2012 Jul; 18(7):1221-31. PubMed ID: 22147427
[TBL] [Abstract][Full Text] [Related]
17. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
[TBL] [Abstract][Full Text] [Related]
18. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
[TBL] [Abstract][Full Text] [Related]
20. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]